(Q35783714)

10 August 2017

1 reference

title

Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride (English)

1 reference

10 August 2017

1 reference

Mary T Korytkowski

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

24

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

606-620

1 reference

Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Insulinotropic meglitinide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Comparative tolerability of sulphonylureas in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Oral therapies for diabetic hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Insulin secretion in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Relationships Between Fasting Plasma Glucose Levels and Insulin Secretion During Intravenous Glucose Tolerance Tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

The crux of the UGDP. Spurious results and biologically inappropriate data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Impairment of myocardial protection in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Repaglinide versus glyburide: a one-year comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Nateglinide therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

21 January 2018

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.606.34752

10.1592/PHCO.24.6.606.34752

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference